Health Canada approves new drug to treat patients with Amyotrophic Lateral Sclerosis (ALS)

Thursday, October 4, 2018 Drug News
Email Print This Page Comment bookmark
Font : A-A+

Priority review granted in light of limited options to treat the disease

OTTAWA, Oct. 4, 2018 /CNW/ - Amyotrophic

Lateral Sclerosis (ALS) is a debilitating degenerative disease that gradually causes muscle weakness and disability. Health Canada recognizes that patients with ALS and their families are anxious to access drugs that
could help.

Given the limited treatment options for patients with ALS, Health Canada reviewed the drug edaravone through its priority review process, which accelerates access to drugs and medical devices for Canadians. This means that the Department completed its review of the drug in 180 days, rather than the typical 300 days. As of today, edaravone is approved for sale in Canada for the treatment of ALS.

While its priority review was ongoing, Health Canada also worked with the manufacturer of edaravone and the ALS network to make the drug available through the Department's Special Access Programme (SAP). Health Canada will continue to work with the manufacturer to facilitate access to edaravone until the authorized drug is available on the Canadian market, reimbursement recommendations have been issued by the Canadian Agency for Drugs and Technologies in Health (CADTH) and l'Institut national d'excellence en santé et en services sociaux (INESSS), and funding decisions have been made by public and private drug plans.

Health Canada is committed to prioritizing the review of certain drugs when there are limited treatment options available.

Quick Facts

  • ALS (also known as Lou Gehrig's disease) is a disease that gradually causes muscle weakness and disability because the brain progressively loses its capacity to communicate with the muscles of the body. Over time, patients living with ALS will typically experience a progressive loss of their ability to walk, talk, eat, swallow, and eventually breathe.
  • An estimated 3,000 Canadians are currently living with ALS. Most people with ALS will die within a few years of the diagnosis.
  • To further reduce any potential delays in accessing edaravone, the Canadian Agency for Drugs and Technologies in Health (CADTH) and l'Institut national d'excellence en santé et en services sociaux (INESSS) started reviewing the drug for possible reimbursement through publicly funded drug plans while Health Canada's review was still underway.
  • As it does with all drugs authorized for sale in Canada, Health Canada will continue to monitor edaravone for any safety concerns and will take appropriate action if required.

Associated Links

Product Monograph

 

SOURCE Health Canada



Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions

News A - Z

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

News Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Find a Doctor

Press Release Category

Press Release Archive

Stay Connected

  • Available on the Android Market
  • Available on the App Store